|
Daniel's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Estuary raised $93 million for a kidney gene therapy, while Setara secured $90 million to advance Actio’s genetics-driven rare disease pipeline.
The top 10 stories from Fri Oct 30, 2026 07:06 AM to Mon Nov 2, 2026 07:07 AM
Generated November 2, 2026 at 7:07 AM
|
|
|
#1 BioVenture VoiCes Episode 51: Vianti Capital's Arjun Goyal Published 2026-11-02 Vianti Capital founder Arjun Goyal discusses his immigrant upbringing, medical practice, startup experience, and career in venture capital at 5AM Ventures and Vida Ventures. Covered by: biotechtv.com |
#2 Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial. Published 2026-10-31 Zhimeng Biopharma completed patient enrollment in the pivotal Phase 2/3 trial of its investigational ALS drug, CB03-154. Covered by: prnewswire.com |
#3 Finance Watch: Biotech Companies Scare Up Big VC Money As October Ends Published 2026-10-30 Dren Bio raised $350 million, Pathos AI secured $237 million, and Warp Sciences raised $215 million; Flagship formed Etcelera, while Setara launched with $90 million. Covered by: insights.citeline.com |
#4 US Biopharma IPO Total Nears $9bn As Bambusa, Aspen Launch Offerings Published 2026-10-30 Bambusa and Aspen’s offerings bring the US biopharma IPO count to 29, with total proceeds nearing $9 billion. Covered by: insights.citeline.com, endpoints.news |
#5 What made Estuary’s kidney gene therapy bet investable Published 2026-10-30 Estuary raised $93 million in Series A funding to develop a one-time gene therapy for autosomal dominant polycystic kidney disease, amid competition from other treatment approaches. Covered by: biocentury.com |
#6 Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio deal Published 2026-10-30 Setara Biosciences spun out Actio Biosciences’ remaining genetics-driven pipeline after its epilepsy drug deal with Jazz Pharmaceuticals and secured $90 million in new funding. Covered by: endpoints.news, biopharmadive.com, fiercebiotech.com, biospace.com |
#7 Post-Hoc Live: Is biotech’s future full of zero- and one- employee startups? Published 2026-10-30 Anthropic acquired Mithril Medicine, a biotech run by one employee with AI and contractors, prompting discussion about whether such lean startups signal biotech’s future. Covered by: endpoints.news |
#8 Anthropic's Nathan Frey on biopharma partners, M&A and pipeline Published 2026-10-30 Nathan Frey, who leads drug discovery research at Anthropic after its acquisition of Coefficient Bio, discussed biopharma partnerships, mergers and acquisitions, and the company’s pipeline. Covered by: endpoints.news |
#9 BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight Published 2026-11-02 The FDA is expected to decide by Nov. 27 whether to approve BridgeBio Pharma’s BBP-418, which could become the first therapy for limb-girdle muscular dystrophy. Covered by: biospace.com |
#10 Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more Published 2026-10-31 Endpoints Weekly’s Halloween edition covers Anthropic’s one-person biotech acquisition and Jake Van Naarden’s dealmaking strategy. Covered by: endpoints.news |
